3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Melanoma
1
Lung Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Advanced or Metastatic Solid Malignancies
1
Advanced Malignancies
1
Adenocarcinoma
1
Interventions
Nivolumab
2
Docetaxel
2
sitravatinib
1
pembrolizumab
1
Saline Solution
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Non-Squamous Non-Small Cell Lung Cancer
×
sitravatinib
×
1 year
×
Clear all
NCT03906071
2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3
Completed
577 enrolled
22 charts